Top
Summary
All studies
Hospitalization
Serious outcomes
Viral clearance
RCTs
Peer-reviewed
All outcomes

Feedback
Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
Top
All cetylpyridinium chloride..
 
Feedback
Home
c19early.org COVID-19 treatment researchCetylpyridinium ChlorideCetylpyridin.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 cetylpyridinium chloride studies

Home
Post
Share
@CovidAnalysis
StudiesStudies
FeedbackFeedback
All studies   Hospitalization   Serious outcomes   Viral clearance   RCTs   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies 68% 1 23 Improvement, Studies, Patients Relative Risk Hospitalization 68% 1 23 Viral clearance 83% 1 22 RCTs 68% 1 23 Late 68% 1 23 Cetylpyridinium Chloride for COVID-19 c19early.org November 2024 FavorsCPC Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rengifo (DB RCT) 68% 0.32 [0.01-7.20] hosp. 0/12 1/11 CT​1​ Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.49 Late treatment 68% 0.32 [0.01-7.20] 0/12 1/11 68% lower risk All studies 68% 0.32 [0.01-7.20] 0/12 1/11 68% lower risk 1 cetylpyridinium chloride COVID-19 study c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.49 Effect extraction pre-specified(most serious outcome) ​1​ CT: study uses combined treatment Favors CPC Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rengifo (DB RCT) 68% 0.32 [0.01-7.20] hosp. 0/12 1/11 CT​1​ Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.49 Late treatment 68% 0.32 [0.01-7.20] 0/12 1/11 68% lower risk All studies 68% 0.32 [0.01-7.20] 0/12 1/11 68% lower risk 1 cetylpyridinium chloride COVID-19 hospitalization result c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.49 ​1​ CT: study uses combined treatment Favors CPC Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rengifo (DB RCT) 68% 0.32 [0.01-7.20] hosp. 0/12 1/11 CT​1​ Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.49 Late treatment 68% 0.32 [0.01-7.20] 0/12 1/11 68% lower risk All studies 68% 0.32 [0.01-7.20] 0/12 1/11 68% lower risk 1 cetylpyridinium chloride COVID-19 serious outcome c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.49 Effect extraction pre-specified(most serious outcome) ​1​ CT: study uses combined treatment Favors CPC Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rengifo (DB RCT) 83% 0.17 [0.02-1.20] viral+ 1/12 5/10 CT​1​ Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.075 Late treatment 83% 0.17 [0.02-1.20] 1/12 5/10 83% lower risk All studies 83% 0.17 [0.02-1.20] 1/12 5/10 83% lower risk 1 cetylpyridinium chloride COVID-19 viral clearance result c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.075 ​1​ CT: study uses combined treatment Favors CPC Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rengifo (DB RCT) 68% 0.32 [0.01-7.20] hosp. 0/12 1/11 CT​1​ Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.49 Late treatment 68% 0.32 [0.01-7.20] 0/12 1/11 68% lower risk All studies 68% 0.32 [0.01-7.20] 0/12 1/11 68% lower risk 1 cetylpyridinium chloride COVID-19 Randomized Controlled Trials c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.49 Effect extraction pre-specified(most serious outcome) ​1​ CT: study uses combined treatment Favors CPC Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rengifo (DB RCT) 68% 0.32 [0.01-7.20] hosp. 0/12 1/11 CT​1​ Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.49 Late treatment 68% 0.32 [0.01-7.20] 0/12 1/11 68% lower risk All studies 68% 0.32 [0.01-7.20] 0/12 1/11 68% lower risk 1 cetylpyridinium chloride COVID-19 peer reviewed studies c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.49 Effect extraction pre-specified(most serious outcome) ​1​ CT: study uses combined treatment Favors CPC Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rengifo (DB RCT) 68% 0.32 [0.01-7.20] hosp. 0/12 1/11 CT​1​ Improvement, RR [CI] Treatment Control Rengifo (DB RCT) 83% 0.17 [0.02-1.20] viral+ 1/12 5/10 CT​1​ Cetylpyridinium chloride COVID-19 outcomes c19early.org November 2024 ​1​ CT: study uses combined treatment Favors CPC Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0